BioLife Solutions: director Catherine Coste sold 13,871 shares

What happened Catherine Coste, director, disposed of 13,871 shares of BioLife Solutions common stock on Oct 6, 2026 in connection with the merger described in the filing. Under the merger terms each share was converted into $11.25 in cash and 0.1442 shares of Repligen common stock, equal to $156,048.75 cash and 2,000.1982 Repligen shares for the reported holding.

Key details

• Transaction date: Oct 6, 2026; transaction code: D (disposition to the issuer).
• Per-share consideration: $11.25 in cash plus 0.1442 Repligen shares.
• Total reported consideration for 13,871 shares: $156,048.75 cash and 2,000.1982 Repligen shares.
• Shares owned after the transaction: not stated in the provided filing excerpt.
• Footnote F1: the disposition reflects the consummation of the first merger under the merger agreement dated Jul 21, 2026; conversion terms described above.
• Filing date: Oct 8, 2026.

Why it may matter

• This was a disposition to the issuer under merger terms (shares converted as part of the transaction), not a typical open-market sale.
• A filing does not show why the insider traded or why the company acted.